Covered recipient · General Payments record
JOSEPH F YACOVONE
Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$28,370.00
45 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $28,370.00 | 45 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $16,745.00 | 33 |
| PFIZER INC. | $11,625.00 | 12 |
Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOSEPH F YACOVONE
NPI 1245255538 · CMS profile ID 1110599
Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology
MIDDLETOWN, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1245255538?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOSEPH F YACOVONE, NPI 1245255538, CMS profile ID 1110599. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245255538?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JOSEPH F YACOVONE, NPI 1245255538, CMS profile ID 1110599. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245255538?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JOSEPH F YACOVONE, NPI 1245255538, CMS profile ID 1110599, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1245255538?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
45 matching records · $28,370.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–45 of 45.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $150.00 | 12/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695887693 | CMS |
| Merck Sharp & Dohme Corporation | $1,590.00 | 12/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695887695 | CMS |
| Merck Sharp & Dohme Corporation | $360.00 | 12/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695888029 | CMS |
| Merck Sharp & Dohme Corporation | $810.00 | 12/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695888037 | CMS |
| Merck Sharp & Dohme Corporation | $630.00 | 12/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695889005 | CMS |
| PFIZER INC. | $1,640.00 | 12/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673840417 | CMS |
| Merck Sharp & Dohme Corporation | $1,080.00 | 11/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695887687 | CMS |
| Merck Sharp & Dohme Corporation | $160.00 | 11/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695887697 | CMS |
| Merck Sharp & Dohme Corporation | $540.00 | 11/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695888031 | CMS |
| Merck Sharp & Dohme Corporation | $600.00 | 11/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695888035 | CMS |
| PFIZER INC. | $1,080.00 | 11/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673840479 | CMS |
| Merck Sharp & Dohme Corporation | $1,080.00 | 10/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695887535 | CMS |
| Merck Sharp & Dohme Corporation | $1,440.00 | 10/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695887689 | CMS |
| Merck Sharp & Dohme Corporation | $150.00 | 10/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695887691 | CMS |
| Merck Sharp & Dohme Corporation | $600.00 | 10/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695888033 | CMS |
| Merck Sharp & Dohme Corporation | $150.00 | 10/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695888999 | CMS |
| PFIZER INC. | $1,280.00 | 10/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673840487 | CMS |
| Merck Sharp & Dohme Corporation | $1,500.00 | 09/03/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695832835 | CMS |
| Merck Sharp & Dohme Corporation | $80.00 | 09/03/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695832849 | CMS |
| PFIZER INC. | $120.00 | 09/03/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673840485 | CMS |
| Merck Sharp & Dohme Corporation | $265.00 | 08/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695832839 | CMS |
| Merck Sharp & Dohme Corporation | $300.00 | 08/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695832841 | CMS |
| Merck Sharp & Dohme Corporation | $300.00 | 08/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695832845 | CMS |
| Merck Sharp & Dohme Corporation | $900.00 | 08/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695832851 | CMS |
| PFIZER INC. | $360.00 | 08/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673840483 | CMS |
| Merck Sharp & Dohme Corporation | $780.00 | 07/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695831931 | CMS |
| Merck Sharp & Dohme Corporation | $200.00 | 07/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695832837 | CMS |
| Merck Sharp & Dohme Corporation | $600.00 | 07/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695832847 | CMS |
| PFIZER INC. | $200.00 | 07/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673840481 | CMS |
| Merck Sharp & Dohme Corporation | $160.00 | 06/03/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695700877 | CMS |
| Merck Sharp & Dohme Corporation | $480.00 | 06/03/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695700883 | CMS |
| PFIZER INC. | $1,120.00 | 06/03/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672446179 | CMS |
| Merck Sharp & Dohme Corporation | $200.00 | 05/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695700879 | CMS |
| Merck Sharp & Dohme Corporation | $360.00 | 05/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695700881 | CMS |
| PFIZER INC. | $1,600.00 | 05/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672446191 | CMS |
| Merck Sharp & Dohme Corporation | $420.00 | 04/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695699859 | CMS |
| Merck Sharp & Dohme Corporation | $120.00 | 04/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695700875 | CMS |
| PFIZER INC. | $920.00 | 04/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672446183 | CMS |
| Merck Sharp & Dohme Corporation | $160.00 | 03/06/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695501173 | CMS |
| PFIZER INC. | $1,600.00 | 03/06/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672445816 | CMS |
| Merck Sharp & Dohme Corporation | $160.00 | 02/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695501167 | CMS |
| Merck Sharp & Dohme Corporation | $300.00 | 02/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695501833 | CMS |
| PFIZER INC. | $480.00 | 02/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672446175 | CMS |
| Merck Sharp & Dohme Corporation | $120.00 | 01/02/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695501159 | CMS |
| PFIZER INC. | $1,225.00 | 01/02/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672446187 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $154,491.70 | 22 |
| PY2024 | Recipient | $15,320.00 | 7 |
| PY2024 | Principal investigator | $119,348.50 | 10 |
| PY2023 | Recipient | $177,360.00 | 9 |
| PY2023 | Principal investigator | $33,678.00 | 4 |
| PY2022 | Recipient | $50,880.00 | 5 |
| PY2021 | Recipient | $32,430.00 | 4 |
| PY2020 | Recipient | $14,400.00 | 2 |
| PY2019 | Recipient | $38,610.00 | 3 |
| PY2019 | Principal investigator | $1,600.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
22 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | E.R. Squibb & Sons, L.L.C. | $352.00 | 12/04/2025 | Covered Recipient Physician | A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigators Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy | No dispute reported | 06/30/2026 | 1236001915 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $2,380.00 | 10/03/2025 | Covered Recipient Physician | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1236001913 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $85.00 | 08/08/2025 | Covered Recipient Physician | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1236001911 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $60.00 | 07/03/2025 | Covered Recipient Physician | A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1236001907 |
| Recipient | GlaxoSmithKline, LLC. | $562.50 | 06/11/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192139151 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $19,740.00 | 06/06/2025 | Covered Recipient Physician | A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy | No dispute reported | 06/30/2026 | 1236001897 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $1,245.00 | 06/06/2025 | Covered Recipient Physician | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER | No dispute reported | 06/30/2026 | 1236001901 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $720.00 | 06/06/2025 | Covered Recipient Physician | A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1236001909 |
| Recipient | GlaxoSmithKline, LLC. | $3,262.50 | 05/13/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192139172 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $9,090.00 | 05/05/2025 | Covered Recipient Physician | A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 in Participants with Relapsed or Refractory T-cell Lymphomas in Japan | No dispute reported | 06/30/2026 | 1236001891 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $405.00 | 05/05/2025 | Covered Recipient Physician | A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma after Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 1236001905 |
| Recipient | GlaxoSmithKline, LLC. | $11,161.50 | 04/15/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192139156 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $4,340.00 | 04/03/2025 | Covered Recipient Physician | A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer | No dispute reported | 06/30/2026 | 1236001899 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $180.00 | 04/03/2025 | Covered Recipient Physician | A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigators Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1236001903 |
| Recipient | GlaxoSmithKline, LLC. | $22,724.25 | 03/13/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192139144 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $75.00 | 03/06/2025 | Covered Recipient Physician | A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1236001895 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $75.00 | 03/06/2025 | Covered Recipient Physician | PET ( Positron Emission Tomography) Response Criteria in Solid Tumors | No dispute reported | 06/30/2026 | 1236001917 |
| Recipient | GlaxoSmithKline, LLC. | $12,828.95 | 02/12/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192139163 |
| Recipient | Eli Lilly and Company | $2,535.00 | 01/31/2025 | Covered Recipient Physician | A PHASE 2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | No dispute reported | 06/30/2026 | 1187876357 |
| Recipient | GlaxoSmithKline, LLC. | $14,850.00 | 01/15/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192139757 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $47,205.00 | 01/03/2025 | Covered Recipient Physician | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1236001889 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $615.00 | 01/03/2025 | Covered Recipient Physician | A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1236001893 |